Rezolute, Inc.
NASDAQ:RZLTBiotechnology
+$0.30 today
- Market cap
- $411.10M
- Beta
- 0.65
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$0.78
Volume 2.93M
Average 2.03M
RZLT EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Rezolute, Inc.NASDAQ: RZLT
EPS (Basic) · Q3 FY2026 · quarter ended Mar 2026
EPS (Basic) remains negative
Q3 FY2026 EPS (Basic) was -$0.16, compared with -$0.27 a year earlier. Trailing-twelve-month EPS (Basic) was -$0.82.
Context
- EPS (Basic) grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 7 analysts of -$0.7 (+28.6%) for the fiscal year ending Jun 2026, a step up from the +26.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.16+27.3% QoQ
- Last fiscal yearJun 2025
- -$0.98+26.3% YoY
- LTMMar 2026
- -$0.82+29.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +40.7% | +43.1% | +2.4 pp |
| 1 year | +26.3% | +28.6% | +2.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (0.98) USD
- Year-over-year change
- +26.3%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | (0.98) | +26.3% |
| FY2024 | 2024-06-30 | (1.33) | -31.7% |
| FY2023 | 2023-06-30 | (1.01) | +55.3% |
| FY2022 | 2022-06-30 | (2.26) | +16.9% |
| FY2021 | 2021-06-30 | (2.72) | — |
EPS (Basic) vs competitors
How RZLT compares with its peers on the latest reported figures
- RZLT's LTM Mar 2026 EPS (Basic) of -$0.82 is the 3rd highest of the 5 companies compared; the peer median is -$0.65.
- Its year-over-year change of +29.3% is the 4th highest of 5, against a peer median of +137.2%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $2.18 | +214.9% | — | |
| LTM Mar 2026 | $0.19 | +191.6% | -38.3% | |
| LTM Mar 2026 | -$0.82 | +29.3% | — | |
| LTM Mar 2026 | -$1.49 | +82.9% | — | |
| LTM Mar 2026 | -$6.11 | -3.9% | — | |
| Peer median (excluding RZLT) | -$0.65 | +137.2% | -38.3% | |
Competitors are the stored peer set for RZLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 13K | 0 | 0 | 0 | 0 |
| Gross Profit | (13K) | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 14.99M | 32.49M | 43.81M | 55.74M | 61.53M |
| Selling, General & Admin | 7.91M | 9.36M | 12.18M | 14.68M | 18.37M |
| Operating Expenses | 22.88M | 41.84M | 55.99M | 70.42M | 79.89M |
| Depreciation & Amortization | 13K | 13K | 30K | 36K | 31K |
| EBITDA | (20.51M) | (39.24M) | (51.76M) | (68.42M) | (74.38M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (22.89M) | (41.84M) | (55.99M) | (70.42M) | (79.89M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 63K | 80K | 4.21M | 4.87M | 5.48M |
| Interest Expense | 375K | 1.81M | 0 | 0 | 0 |
| Other Income / Expenses | 1.99M | 783K | 4.2M | 1.96M | 5.48M |
| Income Before Tax | (20.9M) | (41.06M) | (51.79M) | (68.46M) | (74.41M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (20.9M) | (41.06M) | (51.79M) | (68.46M) | (74.41M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.72) | (2.26) | (1.01) | (1.33) | (0.98) |
| EPS (Diluted) | (2.72) | (2.32) | (1.01) | (1.33) | (0.98) |
| Weighted Avg Shares | 7.67M | 18.2M | 51.19M | 51.47M | 76M |
| Weighted Avg Shares (Diluted) | 7.67M | 19.49M | 51.19M | 51.47M | 76M |
Rezolute, Inc.
NASDAQ:RZLT
Intrinsic Alpha fair value
Locked
Current Price
$4.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.